FI83476B - Foerfarande foer framstaellning av en beredning av 7 -difluorometyltioacetamido-7 -metoxi-3-/1-(2 -hydroxialkyl)-1h-tetrazol-5-yl/tiometyl-1-detia-1-oxa-3-cefem-4 -karboxisyra. - Google Patents

Foerfarande foer framstaellning av en beredning av 7 -difluorometyltioacetamido-7 -metoxi-3-/1-(2 -hydroxialkyl)-1h-tetrazol-5-yl/tiometyl-1-detia-1-oxa-3-cefem-4 -karboxisyra. Download PDF

Info

Publication number
FI83476B
FI83476B FI843261A FI843261A FI83476B FI 83476 B FI83476 B FI 83476B FI 843261 A FI843261 A FI 843261A FI 843261 A FI843261 A FI 843261A FI 83476 B FI83476 B FI 83476B
Authority
FI
Finland
Prior art keywords
process according
difluoromethylthioacetamido
detia
oxa
methoxy
Prior art date
Application number
FI843261A
Other languages
English (en)
Finnish (fi)
Other versions
FI843261A (fi
FI843261A0 (fi
FI83476C (sv
Inventor
Kazuhiro Shima
Masayoshi Inoue
Takayuki Tsukada
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of FI843261A0 publication Critical patent/FI843261A0/fi
Publication of FI843261A publication Critical patent/FI843261A/fi
Publication of FI83476B publication Critical patent/FI83476B/fi
Application granted granted Critical
Publication of FI83476C publication Critical patent/FI83476C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)

Claims (7)

1. Förfarande för framstälining av en lyofiliserad beredning av ett antibakteriellt ämne, 7B-difluorometyl-tioacetamido-7a-metoxi-3-[1-(2-hydroxialkyl)-1H- 5 tetrazol-5-yl]tiometyl-l-detia-l-oxa-3-cefem-4-karboxi- syraalkalimetallsalt, kännetecknat av att det omfattar av lösning av det antibakteriella alkalimetallsaltet och ett stabiliseringsmedel, som utgöres av glukos, fruktos, maltos eller ett aikaiimetä11sait av svavelsyrlighet, 10 svavelsyra, klorvätesyra, bärnstenssyra, fumarsyra eller maleinsyra, i ett sterilt vattenhaltigt lösningsmedel, neutralisation av lösningen tili ett pH-värde av 5 - 8, frysning vid en temperatur mellan -10 och -60 °C under 2 minuter till 10 timmar och torkning av det frysta 15 materialet under högvakuum av mellan 0,005 och 1 millibar under 5-72 timmar.
2. Förfarande enligt krav 1, kännetecknat därav, att det antibakteriella ämnet är 7B-difluorometyltioacet-amido-7a-metoxi-3-[1-(2-hydroxietyl)-lH-tetrazol-5-yl]- 20 tiometyl-l-detia-l-oxa-3-cefem-4-karboxisyranatriumsalt.
3. Förfarande enligt krav 1, kännetecknat därav, att alkalimetallen utgöres av natrium.
4. Förfarande enligt krav 1, kännetecknat därav, att förhällandet av stabiliseringsmedlet tili det antibak- 25 teriella saltet är mellan 0,01 och 0,5 viktdelar.
5. Förfarande enligt krav 4, kännetecknat därav, att förhällandet är mellan 0,02 och 0,3 viktdelar.
6. Förfarande enligt krav 1, kännetecknat därav, att förfarandet genomföres genom flask-, sprutnings- eller 30 bricklyofilisering.
7. Förfarande enligt krav 1, kännetecknat därav, att produkten förvaras under torr kvävgas.
FI843261A 1983-08-22 1984-08-17 Förfarande för framställning av en beredning av 7 -difluorometyltioac etamido-7 -metoxi-3-/1-(2-hydroxialkyl)-1H-tetrazol-5-yl/tiometyl-1-d etia-1-oxa-3-cefem-4-karboxisyra FI83476C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP58153938A JPS6045514A (ja) 1983-08-22 1983-08-22 安定な抗菌性凍結乾燥製剤
JP15393883 1983-08-22

Publications (4)

Publication Number Publication Date
FI843261A0 FI843261A0 (fi) 1984-08-17
FI843261A FI843261A (fi) 1985-02-23
FI83476B true FI83476B (fi) 1991-04-15
FI83476C FI83476C (sv) 1991-07-25

Family

ID=15573358

Family Applications (1)

Application Number Title Priority Date Filing Date
FI843261A FI83476C (sv) 1983-08-22 1984-08-17 Förfarande för framställning av en beredning av 7 -difluorometyltioac etamido-7 -metoxi-3-/1-(2-hydroxialkyl)-1H-tetrazol-5-yl/tiometyl-1-d etia-1-oxa-3-cefem-4-karboxisyra

Country Status (20)

Country Link
US (1) US4616083A (sv)
EP (1) EP0134568B1 (sv)
JP (1) JPS6045514A (sv)
KR (1) KR910004575B1 (sv)
AR (1) AR242390A1 (sv)
AT (1) ATE38774T1 (sv)
CA (1) CA1231896A (sv)
DE (2) DE3475268D1 (sv)
DK (1) DK163032C (sv)
ES (1) ES535654A0 (sv)
FI (1) FI83476C (sv)
GB (1) GB2145333B (sv)
GR (1) GR80147B (sv)
IE (1) IE57587B1 (sv)
IL (1) IL72731A (sv)
NO (1) NO165223C (sv)
NZ (1) NZ209111A (sv)
PT (1) PT79093B (sv)
SU (1) SU1433390A3 (sv)
ZA (1) ZA846104B (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61130223A (ja) * 1984-11-28 1986-06-18 Shionogi & Co Ltd 抗菌性凍結乾燥製剤
US4808617A (en) * 1985-12-18 1989-02-28 Bristol-Myers Company Lyophilized or precipitated cephalosporin zwitterion and salt combination
DE3801179A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
ES2177522T3 (es) * 1990-11-06 2002-12-16 Nippon Shinyaku Co Ltd Preparacion liofilizada y su procedimiento de realizacion.
US7378408B2 (en) 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
WO2004000323A1 (ja) * 2002-06-21 2003-12-31 Shionogi & Co., Ltd. セフェム化合物の注射用医薬組成物
KR101314500B1 (ko) * 2012-12-28 2013-10-07 제일약품주식회사 안정성이 개선된 옥사세펨 제제 및 그 제조방법
US20140274996A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Tazobactam and ceftolozane antibiotic compositions
EP2777705A1 (en) 2013-03-15 2014-09-17 Cubist Pharmaceuticals, Inc. Ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN106687116B (zh) * 2014-09-04 2020-07-24 盐野义制药株式会社 含有具有儿茶酚基的头孢菌素类的制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA919593A (en) * 1969-03-31 1973-01-23 Nippon Kayaku Kabushiki Kaisha Process for manufacturing a preparation containing finely divided chloramphenicol palmitate
US3993753A (en) * 1974-08-26 1976-11-23 American Home Products Corporation Anhydrous ampicillin stabilization and resultant compositions
US4180571A (en) * 1976-03-25 1979-12-25 Shionogi & Co., Ltd. Arylmalonamido-1-oxadethiacephalosporins
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS5762284A (en) * 1980-10-01 1982-04-15 Sumitomo Chem Co Ltd Stabilizing method
JPS59139385A (ja) * 1982-12-23 1984-08-10 Shionogi & Co Ltd フルオロメチルチオオキサセフアロスポリン

Also Published As

Publication number Publication date
CA1231896A (en) 1988-01-26
PT79093B (en) 1986-08-14
SU1433390A3 (ru) 1988-10-23
IL72731A (en) 1988-04-29
EP0134568A1 (en) 1985-03-20
PT79093A (en) 1984-09-01
NO165223B (no) 1990-10-08
IE57587B1 (en) 1993-01-13
GR80147B (en) 1984-12-18
IE842072L (en) 1985-02-22
DE134568T1 (de) 1985-08-29
GB8420296D0 (en) 1984-09-12
ZA846104B (en) 1985-03-27
IL72731A0 (en) 1984-11-30
JPS6045514A (ja) 1985-03-12
DK399684D0 (da) 1984-08-21
ES8505815A1 (es) 1985-06-16
NZ209111A (en) 1987-02-20
DE3475268D1 (en) 1988-12-29
GB2145333A (en) 1985-03-27
ATE38774T1 (de) 1988-12-15
JPH0370688B2 (sv) 1991-11-08
EP0134568B1 (en) 1988-11-23
KR850001687A (ko) 1985-04-01
AR242390A1 (es) 1993-03-31
DK163032C (da) 1992-06-15
KR910004575B1 (ko) 1991-07-06
US4616083A (en) 1986-10-07
FI843261A (fi) 1985-02-23
NO843313L (no) 1985-02-25
FI843261A0 (fi) 1984-08-17
GB2145333B (en) 1987-01-07
FI83476C (sv) 1991-07-25
DK399684A (da) 1985-02-23
DK163032B (da) 1992-01-13
NO165223C (no) 1991-01-30
ES535654A0 (es) 1985-06-16

Similar Documents

Publication Publication Date Title
FI83476B (fi) Foerfarande foer framstaellning av en beredning av 7 -difluorometyltioacetamido-7 -metoxi-3-/1-(2 -hydroxialkyl)-1h-tetrazol-5-yl/tiometyl-1-detia-1-oxa-3-cefem-4 -karboxisyra.
JP3576180B2 (ja) 改良イフォスファミド凍結乾燥組成物
FI75490C (sv) Förfarande för framställning av stabiliserad beta-laktam.
EP0656211B1 (en) Stable lyophilized thiotepa composition
KR830000527B1 (ko) 프로스타사이클린 화합물 제제의 안정화방법
US4808617A (en) Lyophilized or precipitated cephalosporin zwitterion and salt combination
SK283137B6 (sk) Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy
US5095011A (en) Lyophilized cefepime dihydrochloride for parenteral use
CA1308358C (en) Antibacterial lyophilized preparation
JP2761005B2 (ja) セファロスポリン含有注射用組成物
GB2167302A (en) Stable lyophilized antibacterial preparations
JPS5936616A (ja) セフアロスポリン誘導体の安定な医薬組成物
KR100396464B1 (ko) 세푸록심의 나트륨염을 함유하는 약학적 조성물의 안정화방법
KR900000747B1 (ko) 비경구용 세파만돌 나페이트 제제의 제조방법

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: SHIONOGI & CO, LTD